|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Promedior Announces Presentation of Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models
5/1/2012 10:51:54 AM
MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of recombinant human Pentraxin-2 (rPTX-2) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 6-10, 2012, in Ft. Lauderdale, FL. The data to be presented highlight the efficacy of recombinant Pentraxin-2 in suppressing choroidal fibrosis and subretinal vascular leakage in independent models of age-related macular degeneration (AMD) and diabetic retinopathy, and confirm the potent effect of Pentraxin-2 on induction of regulatory macrophage activity in the retina.
|
|
|
|
|
|
|
|
|
|
|